LRI Investments’s Kiniksa Pharmaceuticals KNSA Stock Holding History

LRI Investments’s Portfolio KNSA Stock Details KNSA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$64	Buy	+1	New	+$52	﹤0.01%	1890

Other funds holding KNSA

Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return

PCM

Penn Capital Management Philadelphia, Pennsylvania $1.58B AUM 81.2% 1-Year Est. Return

New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

LTAS

Linden Thomas Advisory Services Charlotte, North Carolina $1.24B AUM 47.37% 1-Year Est. Return

Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return

FEG

Financial Enhancement Group Anderson, Indiana $839M AUM 18.63% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

TFA

Toth Financial Advisory Leesburg, Virginia $1.02B AUM 28.36% 1-Year Est. Return

LRI Investments's KNSA Position: Q2 2026 in Review

LRI Investments opened a new position in Kiniksa Pharmaceuticals (KNSA) in Q2 2026: 1 share worth $64. The stake represents ﹤0.01% of the portfolio and ranks #1890 among its holdings.

56 funds tracked by Wall St. Rank hold KNSA as of Q2 2026.

LRI Investments held 1 share of Kiniksa Pharmaceuticals worth $64 as of Q2 2026.
Kiniksa Pharmaceuticals was a new LRI Investments position in Q2 2026.
Kiniksa Pharmaceuticals made up ﹤0.01% of LRI Investments's portfolio in Q2 2026, its #1890 holding.
56 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q2 2026.

Based on LRI Investments's 13F filing for Q2 2026, filed 14 Jul 2026.